PDE5A and melanoma: The association between PDE5 inhibitors intake and melanoma risk was statistically significant in sildenafil users (RR:1.28, [95% CI, 1.06-1.21]), whereas different effect was found in vardenafil or tadalafil users (RR:1.28, [95% CI, 0.93-1.76]).